avantiavanti schreef op 7 maart 2016 17:07:
Mmmwh stil hier na Henk's reprimande.
Nou ok, dan maar weer even een riedeltje als dit:
Bryan Garnier:
With EUR 1bn in cash, the pipeline looks undervalued
Fair Value EUR63 (+57%) BUY Kempen & Co research:
FY’15 in line; wealth of newsflow upcoming
BUY, PT: €80.00 Jefferies
BUY
Price target €69.00
The pipeline is on-track with Phase III filgotinib RA and Crohn's trials due to start this year. We see 2016E newsflow largely being driven by the cystic fibrosis alliance with AbbVie. We expect this, and the upcoming filgotinib Phase III regulatory discussions, to be the focus. Th. Gilissen:
Wij herhalen ons Aanbevolen advies van onze Speculatieve Pick Galapagos met een koersdoel van EUR 75.Morgan Stanley, KBC, Credit Suisse weten we wel.
Vergeet ik er 1?